Evidence map›Paper›PMID 27491345›Full record

ArticleScientific reports2016

In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen-Induced Retinopathy.

Md Imam Uddin, Stephanie M Evans, Jason R Craft, Megan E Capozzi, Gary W McCollum, Rong Yang, Lawrence J Marnett, Md Jashim Uddin, Ashwath Jayagopal, John S Penn

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. In vivo OScientific reports · 2020
    Article
  12. Article
  13. Article
  14. Therapeutic Effect ofInternational journal of molecular sciences · 2019
    Article
  15. Imaging Retinal Activity in the Living Eye.Annual review of vision science · 2019
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Md Imam UddinDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA.
Stephanie M EvansDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA.
Jason R CraftDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA.
Megan E CapozziDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA.
Gary W McCollumDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA.
Rong YangDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA.
Lawrence J MarnettA. B. Hancock, Jr., Memorial Laboratory for Cancer Research, Departments of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute of Chemical Biology, Center for Molecular Toxicology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
Md Jashim UddinA. B. Hancock, Jr., Memorial Laboratory for Cancer Research, Departments of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute of Chemical Biology, Center for Molecular Toxicology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
Ashwath JayagopalPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.
John S PennDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA.
Vanderbilt University · USRoche (Switzerland) · CH

Funding

Coordinating and Bioinformatics Unit for the MMPC/DiaCompU24DK076169 · NIDDK · AUGUSTA UNIVERSITY · PI MCINDOE, RICHARD A. · 2006 to 2018
$42.4M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6M
RETINOPATHY OF PREMATURITY--UNDERSTAND ITS PATHOGENESISR01EY007533 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENN, JOHN S. · 1993 to 2018
$7.0M
Vanderbilt In Vivo Cellular and Molecular Imaging CenterP50CA128323 · NCI · VANDERBILT UNIVERSITY · PI SHYR, YU · 2008 to 2012
$6.8M
In Vivo Molecular Imaging of the RetinaR01EY023397 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENN, JOHN S., UDDIN, MD IMAM · 2013 to 2022
$3.6M
The calcineurin/NFAT signaling axis in diabetic retinopathy pathogenesisR01EY023639 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENN, JOHN S. · 2014 to 2017
$1.8M
LSM880-Airyscan Confocal Microscope for Large Shared ResourceS10OD021630 · OD · VANDERBILT UNIVERSITY · PI WELLS, K. SAM · 2016 to 2016
$560k
Detection of COX-2-expressing bladder cancer by fluorocoxib AR15CA182850 · NCI · UNIVERSITY OF TENNESSEE KNOXVILLE · PI CEKANOVA, MARIA · 2014 to 2014
$415k
NCI NIH HHS P50 CA128323NCI NIH HHS R15 CA182850NEI NIH HHS P30 EY008126NEI NIH HHS R01 EY007533NEI NIH HHS R01 EY023397NEI NIH HHS R01 EY023639NIDDK NIH HHS P30 DK020593NIDDK NIH HHS U24 DK076169NIH HHS S10 OD021630
6 · The paper itself

Abstract

Ischemia-induced hypoxia elicits retinal neovascularization and is a major component of several blinding retinopathies such as retinopathy of prematurity (ROP), diabetic retinopathy (DR) and retinal vein occlusion (RVO). Currently, noninvasive imaging techniques capable of detecting and monitoring retinal hypoxia in living systems do not exist. Such techniques would greatly clarify the role of hypoxia in experimental and human retinal neovascular pathogenesis. In this study, we developed and characterized HYPOX-4, a fluorescence-imaging probe capable of detecting retinal-hypoxia in living animals. HYPOX-4 dependent in vivo and ex vivo imaging of hypoxia was tested in a mouse model of oxygen-induced retinopathy (OIR). Predicted patterns of retinal hypoxia were imaged by HYPOX-4 dependent fluorescence activity in this animal model. In retinal cells and mouse retinal tissue, pimonidazole-adduct immunostaining confirmed the hypoxia selectivity of HYPOX-4. HYPOX-4 had no effect on retinal cell proliferation as indicated by BrdU assay and exhibited no acute toxicity in retinal tissue as indicated by TUNEL assay and electroretinography (ERG) analysis. Therefore, HYPOX-4 could potentially serve as the basis for in vivo fluorescence-based hypoxia-imaging techniques, providing a tool for investigators to understand the pathogenesis of ischemic retinopathies and for physicians to address unmet clinical needs.

Indexed as

AnimalsDisease Models, AnimalFluorescent DyesHypoxiaIntravital MicroscopyMiceNeovascularization, PathologicOptical ImagingRetinaRetinal DiseasesFluorescent Dyes

Identifiers

PMID27491345
PMCPMC4974503
OpenAlexW2487824879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.